SouthernWorldwide.com – A new obesity treatment, retatrutide, is showing promise in helping individuals preserve muscle mass during weight loss, a significant concern with previous weight-loss medications.
Neuroscientist Dr. Andrew Huberman discussed the potential benefits of retatrutide on Gwyneth Paltrow’s podcast. He acknowledged the advancements in GLP-1 receptor agonist therapies but also highlighted the risks associated with unregulated suppliers.
GLP-1 receptor agonists have gained considerable attention for their roles in biohacking, longevity, and overall wellness. However, these treatments have historically come with a range of side effects.
Huberman explained that earlier weight-loss drugs primarily focused on suppressing appetite, which often led to rapid and substantial calorie deficits. This approach, he noted, frequently resulted in significant loss of lean muscle mass.
“People would lose a ton of weight, but they would also lose muscle mass,” Huberman stated during the podcast, emphasizing the critical need for muscle preservation during weight management.
Retatrutide emerges as a potential solution to this challenge. Unlike older medications that acted on one or two hormone pathways, retatrutide is a triple agonist. This means it stimulates three key hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.
Read more : Car Buying Savings Tips
These hormones play crucial roles in regulating blood sugar levels, appetite, and metabolism. By targeting these three pathways, retatrutide offers a more nuanced approach to weight loss.
“Retatrutide is a more mild agonist of GLP-1,” Huberman elaborated. “It also increases glucagon and … GIP. So, it hits three different pathways, each a bit more subtly.”
In clinical trials, retatrutide is administered as a weekly subcutaneous injection. Early findings suggest that this multi-receptor activation may lead to a lower side effect profile compared to previous generations of these drugs.
Crucially, studies indicate that retatrutide may possess a “muscle sparing effect.” This is a significant development for individuals focused on both weight loss and maintaining physical strength and function.
The drug has the potential to help individuals lose a substantial amount of weight, up to a third of their body weight over approximately a year, while mitigating the loss of lean muscle mass. This is a key advantage for long-term health and fitness.
However, as retatrutide is still an investigational molecule, a significant “gray market” has emerged. Compounding pharmacies and online suppliers are offering products claiming to be retatrutide to meet the growing demand.
Huberman issued a stern warning about these unregulated sources. He pointed out that claims of high purity, such as “99% purity,” can be misleading, as the remaining 1% could contain harmful contaminants.
Specifically, he mentioned the risk of lipopolysaccharides (LPS), a type of bacterial toxin. “LPS will cause inflammation,” Huberman cautioned. “One injection isn’t gonna do it, but multiple injections over time, I could see where that could become problematic.”
Paltrow echoed these concerns, drawing parallels between the current peptide market and the supplement industry in the 1990s. She highlighted the lack of third-party testing and reliance on anecdotal evidence in such unregulated markets.
Both Huberman and Paltrow stressed the importance of consulting with a medical doctor before considering any such therapies. They strongly advised against using products obtained from unverified online sources.
Retatrutide is currently available legally only to participants in clinical trials sponsored by its manufacturer, Lilly. The company is actively evaluating the drug’s safety and efficacy in these studies.
Experts emphasize that retatrutide has not yet been reviewed or approved by any regulatory agency. Therefore, individuals should not seek to obtain or use any substance claiming to be retatrutide outside of a formal clinical trial setting.
